Cordis Corporation, a worldwide leader in the development and manufacture of interventional vascular technology, today announced it will no longer pursue the development of the NEVO Sirolimus-Eluting Coronary Stent in order to focus on other cardiovascular therapies where significant patient need exists. The company will also stop the manufacture of CYPHER and CYPHER SELECT Plus Sirolimus-Eluting Coronary Stents by the end of 2011.
Cypher was the first drug-eluting stent on the market, but ABT’s Xience has rendered Cypher an afterthought in the marketplace.
Nevo, based on technology JNJ acquired in the $1.3B buyout of Conor Medsystems in 2006 (#msg-14870799), made a big splash in 2009 (#msg-37962147). Nevo’s claim to fame was its Swiss-cheese like drug reservoirs in lieu of a drug coating used in other DES products.
In a separate PR today, JNJ said it was taking a $500-600M charge against earnings in the current quarter for “restructuring” of the Cordis division.
“The efficient-market hypothesis may be the foremost piece of B.S. ever promulgated in any area of human knowledge!”
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.